Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 21;15(1):26499.
doi: 10.1038/s41598-025-12583-6.

Non-invasive scoring systems of liver fibrosis predict prognosis in the cohort with myocardial infarction

Affiliations

Non-invasive scoring systems of liver fibrosis predict prognosis in the cohort with myocardial infarction

Esther Wong et al. Sci Rep. .

Abstract

Patients with liver fibrosis and type 2 diabetes mellitus (T2DM) have an increased risk of cardiovascular events. However, long-term prognosis of liver fibrosis and T2DM after acute myocardial infarction (AMI) remain to be investigated. This study compared clinical characteristics and prognosis of AMI patients with T2DM and evidence of liver fibrosis. Patients were stratified into low, intermediate and high-risk for fibrosis, using serum-based non-invasive tests (NITs): Fibrosis-4 Index (FIB-4), Aspartate Aminotransferase to Platelet Ratio Index (APRI) and Non-alcoholic Fatty Liver Disease Fibrosis Score (NFS). The primary outcome was all-cause mortality, Kaplan-Meier curves were constructed for 5-year all-cause mortality. Cox regression analysis was used to determine the independent predictors of mortality, adjusting for confounders. Out of 3287 AMI patients, 1547 were stratified as high-risk by any NIT (mean follow-up duration 2.7 ± 2.3 years). A dose-response relationship was found with increasing mortality risk for higher APRI and NFS scores. High-risk FIB-4 also predicted mortality significantly (adjusted HR [aHR] 1.791, 95% CI 1.436-2.235, p < 0.001). High-risk FIB-4 and APRI independently predicted mortality regardless of T2DM status, while NFS only predicted mortality in T2DM patients. Following AMI, individuals stratified by FIB-4, APRI, NFS as high-risk for liver fibrosis were associated with excess long-term mortality (aHR 1.780, 95% CI 1.442-2.196, p < 0.001). Hence, readily available NITs may be beneficial in risk prognostication of AMI patients.

Keywords: Acute coronary syndrome; Aspartate aminotransferase to platelet ratio index; Fibrosis-4 index; Metabolic dysfunction-associated steatotic liver disease; Non-alcoholic fatty liver disease fibrosis score; Non-invasive tests.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The study was approved by the local institutional review committee in accordance with the revised Declaration of Helsinki (NHG Research—DSRB: 2021/00089-AMD0001). The institutional review board waived the need for written patient consent as this study involved a retrospective analysis of clinically acquired data.

Figures

Fig. 1
Fig. 1
Kaplan-Meier survival curves of all-cause mortality in the AMI cohort stratified based on A) FIB-4 B) APRI and C) NFS. Subgroup analysis of all-cause mortality was performed in individuals without (center) and with T2DM (right). AMI, acute myocardial infarction; FIB-4, Fibrosis-4 index; APRI, Aspartate Aminotransferase (AST) to Platelet Ratio Index; NFS, Non-alcoholic Fatty Liver Disease Fibrosis Score; T2DM, type 2 diabetes mellitus.

Similar articles

References

    1. Di Cesare, M. et al. The heart of the world. Glob Heart. 19, 11. 10.5334/gh.1288 (2024). - PMC - PubMed
    1. Gutierrez-Cuevas, J., Santos, A. & Armendariz-Borunda, J. Pathophysiological molecular mechanisms of obesity: A link between MAFLD and NASH with cardiovascular diseases. Int. J. Mol. Sci.2210.3390/ijms222111629 (2021). - PMC - PubMed
    1. Chew, N. W. S. et al. Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort. Lancet Reg. Health West. Pac.37, 100803. 10.1016/j.lanwpc.2023.100803 (2023). - PMC - PubMed
    1. Goh, R. S. J. et al. The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East asia, South asia, South-East asia, central asia, and high-income Asia Pacific regions. Lancet Reg. Health West. Pac.49, 101138. 10.1016/j.lanwpc.2024.101138 (2024). - PMC - PubMed
    1. Chong, B. et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur. J. Prev. Cardiol.10.1093/eurjpc/zwae281 (2024). - PubMed

MeSH terms

Substances

LinkOut - more resources